BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $15.17 Consensus Target Price from Brokerages

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been given a consensus rating of “Moderate Buy” by the six research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $15.17.

Several equities analysts have commented on BCRX shares. Needham & Company LLC upped their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Barclays upped their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Evercore ISI lifted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Deerfield Management Company L.P. Series C boosted its stake in shares of BioCryst Pharmaceuticals by 62.9% during the second quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock valued at $50,279,000 after purchasing an additional 3,140,804 shares in the last quarter. Geode Capital Management LLC boosted its position in BioCryst Pharmaceuticals by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock valued at $36,776,000 after acquiring an additional 127,708 shares in the last quarter. Fisher Asset Management LLC increased its holdings in shares of BioCryst Pharmaceuticals by 16.9% in the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock valued at $25,369,000 after acquiring an additional 481,359 shares during the period. Two Sigma Advisers LP raised its position in shares of BioCryst Pharmaceuticals by 13.6% in the 3rd quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock worth $16,576,000 after acquiring an additional 261,500 shares in the last quarter. Finally, Rice Hall James & Associates LLC lifted its stake in shares of BioCryst Pharmaceuticals by 4.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock worth $16,444,000 after purchasing an additional 84,102 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Up 1.1 %

BCRX stock opened at $8.02 on Thursday. The stock has a market cap of $1.66 billion, a PE ratio of -13.15 and a beta of 1.76. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $8.88. The company has a 50-day moving average price of $7.62 and a 200 day moving average price of $7.68.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). The business had revenue of $117.10 million for the quarter, compared to analysts’ expectations of $113.99 million. During the same quarter last year, the firm earned ($0.19) EPS. The firm’s quarterly revenue was up 35.1% on a year-over-year basis. Sell-side analysts forecast that BioCryst Pharmaceuticals will post -0.38 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.